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Abstract
Objectives: Major depressive disorder (MDD) is a prevalent psychiatric disorder associated with
impaired patient functioning and reductions in health-related quality of life (HRQL). The present
study describes the impact of MDD on patients' HRQL and examines preference-based health state
differences by patient features and clinical characteristics.
Methods: 95 French primary care practitioners recruited 250 patients with a DSM-IV diagnosis of
MDD for inclusion in an eight-week follow-up cohort. Patient assessments included the
Montgomery Asberg Depression Rating Scale (MADRS), the Clinical Global Impression of Severity
(CGI), the Short Form-36 Item scale (SF-36), the Quality of Life Depression Scale (QLDS) and the
EuroQoL (EQ-5D).
Results: The mean EQ-5D utility at baseline was 0.33, and 8% of patients rated their health state
as worse than death. There were no statistically significant differences in utilities by demographic
features. Significant differences were found in mean utilities by level of disease severity assessed by
CGI. The different clinical response profiles, assessed by MADRS, were also revealed by EQ-5D at
endpoint: 0.85 for responders remitters, 0.72 for responders non-remitter, and 0.58 for non-
responders. Even if HRQL and EQ-5D were moderately correlated, they shared only 40% of
variance between baseline and endpoint.
Conclusions:  Self-reported patient valuations for depression are important patient-reported
outcomes for cost-effectiveness evaluations of new antidepressant compounds and help in further
understanding patient compliance with antidepressant treatment.
Introduction
Major depressive disorder (MDD) is common in primary
care patients [1] with a lifetime prevalence rate in the
French population of 10–25% in women and 5–12% in
men [2]. Depression is associated with marked decreases
in functioning, well being and health-related quality of
life (HRQL) [3,4], and an increases in disability days [5],
use of health services and overall societal costs [6]. Anti-
depressant treatments are effective in reducing depression
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severity [7,8] and in increasing patient functioning and
HRQL [9,10].
The Washington Panel on Cost-Effectiveness in Health
and Medicine recommended the use of HRQL in the eval-
uation of health care interventions [11]. For this purpose,
HRQL measurement needs to express patient health status
on a scale where perfect health and death are valued 1 and
0 respectively. When such quality of life data are com-
bined with corresponding data on the quantity of life,
then the consequences of treatment are measured in units
of Quality-Adjusted Life Years (QALYs) [12]. Where
QALYs are calculated for social decision making purposes
then the HRQL measures used to make the quality adjust-
ment should be based on the preferences of the popula-
tion as a whole. Such social preferences are only available
for a limited number of HRQL measures and for a limited
number of countries. EQ-5D is one such measure that has
been calibrated in this way.
Studies of physical illnesses have suggested that patient's
values for their own health state affect decisions concern-
ing treatment and its outcomes [13-15]. Several studies
focused on establishing utility scores for a variety of
health states in various mental illnesses, including schizo-
phrenia [16], depression in primary care [17], temporary
states of depression [18,19] and treatment-related side
effects [20,21]. Health states in depression have been
characterised by the presence or absence of symptoms,
and depressed patients are usually categorised as respond-
ers and remitters using classical rating scales [22]. As
responders sometimes present residual depressive symp-
toms, we classify patients as "Responder remitters",
"Responders non-remitter" and "Non-responders".
The objectives of this paper are to describe the impact on
HRQL of patients with MDD treated in a primary care set-
ting, and to examine variations in terms of patients'
demographic and clinical characteristics.
Material and methods
Design and patient sample
This national, multicentre, prospective, non-comparative
cohort study was designed so as to reproduce the guide-
lines for management of depression in primary care. The
scheduled follow-up period was two months, with assess-
ments at baseline (D0), four weeks later (D28) and eight
weeks later (D56).
The patients included in this study were recruited from an
outpatient population, aged 18 and older, who consulted
general practitioners for a new episode of MDD according
to the DSM-IV [23]), and who were not treated with any
antidepressant before inclusion. Patients whose symp-
tomatology suggested schizophrenia or other psychotic
symptoms, according to DSM-IV, were not included in
this study. According to their experience and daily prac-
tice, general practitioners initiated an antidepressant treat-
ment at baseline.
Data collection
Patients' characteristics
Patient profiles were created at baseline by recording age,
gender, lifestyle, place of residence, socio-professional cat-
egory and current professional status.
Clinical measures
Physicians assessed the severity of depressive symptoms
using the Montgomery-Asberg Depression Rating Scale
(MADRS) [24] and the Clinical Global Impression of
Severity (CGI-S) scale. The CGI was rated by physicians on
a seven-point Likert scale ranging from 1 = "Normal, not
ill at all" to 7 = "Among the most ill patients".
Qualitative outcomes derived from rating scales, like
response to treatment or remission, are usually used in
both clinical trials and economic evaluations of new anti-
depressant agents [22]. Using MADRS scores at D56,
patients were classified into two groups: those that had
scores lower or equal to 12 were considered as "Remit-
ters", the others were considered as "Non-remitters".
Patients who had a decrease of at least 50% in relation to
baseline score were considered as "Responder", whereas
the others were "Non-responders". These two patients
groupings led to the creation of three mutually exclusive
groups: "Responder remitters", "Responders non-remit-
ter" and "Non-responders".
Patient Reported Outcomes
The outcome measures used in this study were the 36-
item Short-Form Health Survey (SF-36), the Quality of
Life in Depression Scale (QLDS) and the EQ-5D.
The SF-36 is a generic HRQL measure consisting of eight
dimensions assessing physical functioning (PF), role lim-
itations due to physical problems (RP), bodily pain (BP),
general health (GH), vitality (VT), mental health (MH),
role limitations due to emotional problems (RE) and
social functioning (SF) [25]. Two summary scores also
assess both physical (PCS) and mental (MCS) facets [26].
All scale scores range from 0 (the worst HRQL) to 100 (the
best HRQL).
The QLDS is a 34-item depression-specific HRQL instru-
ment that assesses the ability and capacity of individuals
to satisfy their daily needs [27,28]. Each item is answered
by Yes or No. An overall HRQL score is obtained by sum-
ming the 34 items. The results range from 0 (the highest
HRQL) to 34 (the lowest HRQL).Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/20
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EQ-5D is a generic measure of HRQL in which health sta-
tus is defined in terms of 5 dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/depres-
sion [29]. Each dimension has three qualifying levels of
response roughly corresponding to 'no problems', 'some
difficulties/problems', and 'extreme difficulties'. EQ-5D
defines a total of 243 unique health states. The impor-
tance of each of these states can be determined in a
number of different ways. For the purpose of cost-utility
analysis and other situations where the consequences of
treatment are measured in terms of QALYs, these weights
are typically established using utility measurement tech-
niques such as Standard Gamble or Time Trade-Off (TTO)
[12]. For the purposes of this present study, TTO weights
elicited from a large national survey of the UK population
were used [30]. Information collected using EQ-5D can be
reported in terms of its individual dimensions and as a
single index score (EQ-5DST).
Data analysis
Continuous variables were expressed by means and stand-
ard deviations, whereas categorical data were presented
using frequency and percentage. The scales were scored
using scoring algorithms described by the scale designers.
Student's t-tests, ANOVA, Mann-Whitney, or Kruskal-Wal-
lis tests were performed when appropriate to compare
mean scores across subgroups. Regression analyses were
used to examine the relationships between differences in
the utility-weighted EQ-5DST and demographics, clinical
response and HRQL measures. Several selection proce-
dures (backward, stepwise) were tested in order to check
the robustness of the model. The impact of each predictor
was assessed with estimates and their 95% confidence
interval. The data were analysed using the SAS software
version 8.2. For all tests, the type I error was set to 0.05.
Results
Sample characteristics
Ninety-five physicians enrolled 250 patients between May
and November 2002. Patient age ranged from 18 to 92
years, with a mean of 44.2 ± 14.1 years (mean ± standard
deviation). The sex ratio (males/females) was 0.4. The
mean MADRS score was 32.7 ± 7.7, ranging from 13 to 53.
This high level of severity was also revealed by the CGI:
about 85% of patients were rated "markedly ill" or more
severely. The demographic and clinical characteristics of
the sample are reported in Table 1.
Among the 250 included patients, 24 were lost to follow-
up (9.6%). Their sociodemographics and clinical charac-
Table 1: Patient sociodemographics and clinical characteristics
Frequency Percentage
Gender a
Male 69 27.7
Female 180 72.3
Professional status b
Farmer 1 0.4
Craftsman 15 6.1
Manager 26 10.6
Intermediate profession 44 17.9
Employee 78 31.7
Manual labourer 19 7.7
Retired 27 11.0
Other 36 14.6
Place of residence c
Urban area 185 74.3
Rural area 64 25.7
CGI-Severity at baseline
First signs 0 0.0
Slightly ill 6 2.4
Moderately ill 36 14.4
Markedly ill 173 69.2
Seriously ill 35 14.0
Clinical response
Responder remitters 144 64.3
Responders non-remitter 34 15.2
Non-responders 46 20.5
a missing value = 1; b missing values = 4; c missing values = 26.Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/20
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teristics were not significantly different from those of the
226 completers, so that all subsequent analyses were per-
formed on the completers sub-sample.
Impact of MDD on HRQL
At baseline, the mean QLDS score was 20.8 ± 5.8, ranging
from 5 to 31. The mean SF-36 dimension scores for the
total sample were: PF 69.0 ± 24.5, RP 22.4 ± 30.7, BP 52.0
± 23.5, GH 38.3 ± 17.3, VT 22.2 ± 13.1, MH 24.5 ± 12.1,
RE 9.1 ± 21.3 and SF 30.2 ± 17.1. The mean SF-36 sum-
mary scores were PCS 43.6 ± 9.2 and MCS 21.1 ± 6.6. The
mean EQ-5DST score was 0.33 ± 0.25, ranging between -
0.59 and 0.85. It was noteworthy that 8% of the study
population had an EQ-5DST score of worse than death, i.e.
less than zero.
During follow-up, all the dimensions rated improved
(Table 2). The mean EQ-5DST scores were 0.68 ± 0.24
(range: [-0.11; 1.00]) and 0.78 ± 0.21 (range: [-0.08;
1.00]) at weeks 4 and 8, respectively.
Comparison of EQ-5DST by demographic and clinical 
features
No significant differences were found in EQ-5DST  by
demographics characteristics (Table 3): men and women
reported the same preference-based score at baseline
(0.32 ± 0.22 vs. 0.32 ± 0.26, respectively) and their scores
increased in a similar manner during follow-up. Younger
patients reported higher utility scores than older patients
at baseline, day 28 and day 56, although this pattern was
not statistically significant.
Significant differences in EQ-5DST were found by disease
severity level assessed by CGI-S, with more severe patients
having lower weighted index scores. At baseline, a mean
difference of 0.12 was observed between "slightly/moder-
ately ill" and "markedly ill" patients (p < 0.05), and 0.18
between "markedly ill" and "seriously ill" patients (p <
0.001). At the end of the follow-up, a mean difference of
0.12 was observed between patients with "first signs of ill-
ness" and "slightly/moderately ill" patients (p < 0.001).
"Slightly/moderately ill" and "markedly ill" patients had
EQ-5DST scores that differed 0.30 on average (p < 0.001).
A mean difference of 0.14 between "markedly ill" patients
and "seriously ill" patients was found (p < 0.05).
Comparison of EQ-5DST by clinical response
Clinical response, defined by MADRS scores, revealed sta-
tistically significant differences between mean EQ-5DST
scores at baseline (p < 0.01), D28 (p < 0.001) and D56 (p
< 0.001) (Table 4).
At baseline, an overall significant difference was found in
comparing the three groups, with a mean difference of
0.14 observed between "Responder remitters" and
"Responder non-remitters" (p < 0.01). During the study
period, EQ-5DST scores increased in all groups of clinical
response. At the end of the follow-up, a statistically signif-
icant mean difference of 0.14 was observed between
Table 2: EQ-5D dimension scores at baseline, D28 and D56
Baseline D28 D56
N%N%N%
Mobility
No difficulties 166 73.5 192 85.0 207 91.6
Some difficulties 58 25.6 34 15.0 19 8.4
Extreme difficulties 2 0.9 0 0.0 0 0.0
Self-care
No difficulties 186 82.3 214 94.7 216 95.6
Some difficulties 38 16.8 12 5.3 10 4.4
Extreme difficulties 2 0.9 0 0.0 0 0.0
Usual activities
No difficulties 56 24.8 133 58.9 172 76.1
Some difficulties 150 66.4 92 40.7 53 23.5
Extreme difficulties 20 8.8 1 0.4 1 0.4
Pain/Discomfort
No difficulties 54 23.9 114 50.4 135 59.8
Some difficulties 153 67.7 108 47.8 90 39.8
Extreme difficulties 19 8.4 4 1.8 1 0.4
Anxiety/Depression
No difficulties 2 0.9 27 11.9 72 31.9
Some difficulties 48 21.2 155 68.6 133 58.8
Extreme difficulties 176 77.9 44 19.5 21 9.3Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/20
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"Responder remitters" and "Responders non-remitter" (p
< 0.001). "Responders non-remitter" and "Non-respond-
ers" had EQ-5DST scores that significantly differed by 0.14
on average (p < 0.05).
Comparison of Patient Reported Outcomes
At each visit, EQ-5DST scores were compared with SF-36
dimension, SF-36 summary and QLDS scores (Table 5) by
computing correlation coefficients. The correlation
between EQ-5DST score and the Mental Health dimension
of the SF-36 was the highest observed, whatever the
assessment (DO: r = 0.49; D28: r = 0.56; D56: r = 0.63). At
baseline, Pearson correlation coefficients were always
greater than 0.30, except for the role-physical and role-
emotional dimensions.
The QLDS was significantly correlated with the EQ-5DST
scores, ranging from -0.43 at baseline to -0.68 at the end
of the follow-up period.
Multivariate analysis
An ordinary least-square regression analysis to predict EQ-
5DST using demographic features, clinical and HRQL evo-
lution only explained 40% of the variance in the weighted
index scores. The statistically significant predictors in the
regression model were differences in Physical Function-
ing, Bodily Pain, General Health and Mental Health
(Table 6).
Discussion
This study evaluated the usefulness of EQ-5D in assessing
health status of primary care patients with major depres-
sive disorder.
The sampling of our study is representative of the primary
care depressed population in France [2]. 8% of the
patients rated their health state as worse than death. This
result is not surprising given the relationship between
depression and suicide [31,32]. Despite different
approaches to measuring health state utilities using stand-
ard gamble, time trade-off or rating scales, the findings of
Table 3: Differences on utility score by demographic and clinical characteristics
Baseline D28 D56
Mean ± SD p Mean ± SD p Mean ± SD p
Gender 0.94 0.48 0.70
Male 0.32 ± 0.22 0.66 ± 0.24 0.79 ± 0.20
Female 0.32 ± 0.26 0.68 ± 0.25 0.77 ± 0.21
Age group 0.76 0.12 0.64
≤30 years 0.35 ± 0.23 0.76 ± 0.24 0.81 ± 0.23
31–65 years 0.32 ± 0.24 0.66 ± 0.25 0.77 ± 0.21
>65 years 0.30 ± 0.38 0.68 ± 0.17 0.79 ± 0.14
Place of 
residence
0.44 <0.01 0.23
Urban area 0.31 ± 0.25 0.65 ± 0.25 0.77 ± 0.21
Rural area 0.34 ± 0.25 0.75 ± 0.22 0.81 ± 0.19
CGI-Severity <0.001 <0.001 <0.001
First signs -- 0.80 ± 0.14 0.86 ± 0.13
Slightly/
Moderately ill
0.45 ± 0.22 0.66 ± 0.23 0.74 ± 0.19
Markedly ill 0.33 ± 0.24 0.40 ± 0.26 0.44 ± 0.27
Seriously ill 0.15 ± 0.21 0.14 ± 0.14 0.30 ± 0.27
Table 4: Utility scores and clinical response during the study period
Baseline D28 D56
Mean ± SD p Mean ± SD p Mean ± SD p
Clinical response <0.01 <0.001 <0.001
Responder remitters 0.35 ± 0.24 0.76 ± 0.18 0.85 ± 0.13
Responders non-remitter 0.21 ± 0.25 0.54 ± 0.26 0.72 ± 0.20
Non-responders 0.30 ± 0.27 0.54 ± 0.30 0.58 ± 0.28Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/20
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our study agree with those previously reported: the base-
line mean utility of an untreated depression was 0.33,
compared to 0.30 for Revicki [21] and 0.32 for Bennett
[33]. Patient-rated EQ-5DST scores after the eight-week fol-
low-up period was 0.78, which is comparable to utilities
reported in other studies (0.79 [33]; 0.74 [21]; 0.76 [34];
0.70 [35]). The main interest is that EQ-5DST values are
easy to collect in large sample surveys due to the brevity of
EQ-5D classification system with its 5 dimensions and 3
levels.
No differences in EQ-5DST  utilities were observed by
demographic characteristics, which is comparable to pre-
vious results in depressed patients [21,34,35]. More
severely depressed patients reported utilities that were
0.30 points lower than less severely depressed patients at
baseline. Several researchers have suggested that differ-
ences in utility greater than 0.05 are clinically important
[12,36]. These findings may reflect clinically important
differences.
As demonstrated in previous studies [21,37], we found
that the EQ-5DST score and other HRQL measures shared
only about 40% of variance. Utilities measure a patient's
preference for their health state, while HRQL scales assess
the patient's report of their functioning and well-being.
Although these two concepts are related they are not iden-
tical [38], and measuring both may lead to a better under-
standing of reasons for non-compliance to treatment
regimens.
There are several limitations that need to be considered
when interpreting the results of this study. First, the study
does not take into account the antidepressant prescribed
or their side effects, which may influence patients' ratings
[21,39]. Second, the concomitant impact of depression
and chronic medical conditions could not be examined in
this sample. It is likely that the health state utilities of
patients with depression, in addition to a chronic medical
disease would be significantly reduced [17]. Lastly, a lim-
itation of the analysis presented in this study relates to the
source of the utility weights used to compute the EQ-5DST.
Given that this was a national study conducted in France
it may have been better to use social preference values
based on the French population. Unfortunately, at the
time of writing these values were not available for EQ-
Table 5: Association between utility score and HRQL
Baseline D28 D56
Correlation Correlation Correlation
Short Form-36 Item
Physical Functioning 0.39*** 0.42*** 0.45***
Role-Physical Limitations 0.28*** 0.51*** 0.47***
Bodily Pain 0.37*** 0.53*** 0.53***
General Health 0.47*** 0.54*** 0.58***
Vitality 0.45*** 0.54*** 0.59***
Mental Health 0.49*** 0.56*** 0.63***
Role-Emotional Limitations 0.26*** 0.46*** 0.49***
Social Functioning 0.44*** 0.54*** 0.59***
Physical Composite Summary 0.42*** 0.51*** 0.50***
Mental Composite Summary 0.34*** 0.49*** 0.58***
Quality of Life for Depression Scale -0.43*** -0.59*** -0.68***
*** p < 0.001
Table 6: Contributors of the difference in EQ-5DST during the study period
Parameter estimate Standard error p-value 95% Confidence 
Interval
Intercept 0.1971 0.0291 <0.001 [0.1396–0.2546]
Physical Functioning 0.0019 0.0007 <0.01 [0.0005–0.0033]
Bodily Pain 0.0016 0.0007 <0.05 [0.0001–0.0030]
General Health 0.0030 0.0009 <0.01 [0.0011–0.0048]
Mental Health 0.0044 0.0009 <0.001 [0.0027–0.0061]Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/20
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5DST. Weights were therefore adopted from a major UK
study that provided the most robust technical estimates
widely used in the evaluation of EQ-5DST in countries that
lack their own national reference data.
Utility scores are needed for calculating QALYs, which are
used as indicators of effectiveness or outcome in eco-
nomic evaluations [35,36,40]. It is debatable whether or
not patient or general population utilities should be used
in cost-effectiveness studies [40]. Nevertheless, patients
with experience in the disease may be the best providers
of health state preference data. Cost-effectiveness studies
are required to help clinicians and health care decision-
makers in determining the impact of new antidepressants
on both patient outcomes and medical or overall societal
costs. Understanding patient preferences for depression
outcomes is important for economic evaluations of new
antidepressants, as well as for understanding patient
behaviour and compliance to antidepressant regimens.
Such a measure can be applied to cost-utility analyses
either within clinical decision modelling studies or within
prospective, randomised clinical trials and offers addi-
tional scope for the analysis and reporting of data derived
from clinical trials of new compounds.
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